$ECOR COULD BE A SIZABLE RALLY ON COST CUTTING UP 15%

******UP PRE MARKET 15% BUT THIS COULD RUN A LOT HIGHER ON THE COMPANIES ANNOUNCEMENT OF RESTRUCTURING AND COST CUTTING, EXTREME RELIEF FOR INVESTORS WHOM WANTED A PRO ACTIVE APPROACH MUCH SOONER. *****

AVERAGE PRICE TARGET $20.50
AVERAGE RECOMMENDATION BUY

COMPANY PROFILE
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company's therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache.